Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity.

Pharmaceuticals led the sector, thanks in part to growing demand for GLP-1 obesity and diabetes drugs. Positive clinical trial readouts in large markets, such as oncology, were another tailwind.

The products are being advertised as more affordable alternatives to blockbuster weight-loss drugs. Here’s what doctors think ...

The Corner Booth Dr. Patricia Brubaker has spent decades researching and speaking on studies relating to the development of ...

The line includes thoughtfully portioned meals that offer at least 20 grams of protein and contain essential nutrients such ...

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

While both berberine and Ozempic may lead to weight loss, they are very different things. It’s “inaccurate and misleading” to ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.

Plus: The story behind the award-winning science that led to Ozempic, the next astronaut launch and why homework is good for ...

An unusual placebo effect in Aligos Therapeutics’ Phase IIa trial is driving shareholder skepticism for its metabolic ...

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...